BackStealth BioTherapeutics Overview

Stealth BioTherapeutics Accounts Payable

Track Stealth BioTherapeutics's accounts payable ($4.1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$4.12M
10.78% YoYΔ $-498000.00 vs prior year quarter

Peer average / median

Loading

Stealth BioTherapeutics Accounts Payable History

Loading

Stealth BioTherapeutics vs. peers: Accounts Payable Comparison

Loading

Stealth BioTherapeutics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Stealth BioTherapeutics (MITO) FAQ

As of the most recent data (March 2022), MITO shows a accounts payable of $4.1M. That compares with $4.6M in the prior-year period — down 10.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MITO's accounts payable is now $4.1M (was $4.6M) — a 10.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Stealth BioTherapeutics is outperforming or lagging.

Tracking MITO's accounts payable over time shows whether Stealth BioTherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $4.1M That compares with $4.6M in the prior-year period — down 10.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Stealth BioTherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $4.1M) with ownership activity and broader fundamentals.

Stealth BioTherapeutics's accounts payable is $4.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.